Kiniksa Pharmaceuticals International financials
$75.73−0.49%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $677.6M | $423.2M | $270.3M | $220.2M | $38.5M | — | — | — |
| Gross profit | $599.9M | $362.3M | $236.9M | $173.2M | $28.6M | — | — | — |
| Gross margin | 88.5% | 85.6% | 87.6% | 78.7% | 74.2% | — | — | — |
| Operating income | $77.2M | -$45.6M | -$25.2M | $9.8M | -$156.6M | -$157.4M | -$170.0M | -$108.2M |
| Net income | $59.0M | -$43.2M | $14.1M | $183.4M | -$157.9M | -$161.4M | -$161.9M | -$103.2M |
| Net margin | 8.7% | −10.2% | 5.2% | 83.3% | −409.7% | — | — | — |
| Diluted EPS | $0.75 | $-0.60 | $0.20 | $2.60 | $-2.30 | $-2.61 | $-2.99 | $-3.49 |
| EBITDA | $78.8M | -$43.9M | -$22.9M | $12.2M | -$154.3M | -$155.0M | -$167.9M | -$107.9M |
| Operating cash flow | $138.0M | $25.7M | $13.3M | $5.8M | -$126.3M | -$136.5M | -$158.4M | -$81.0M |
| Free cash flow | $136.4M | $25.4M | $13.2M | $5.7M | -$126.7M | -$136.8M | -$161.6M | -$86.3M |
| Diluted shares | 79.0M | 71.4M | 71.9M | 70.4M | 68.6M | 61.8M | 54.0M | 29.5M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $165.6M | $183.6M | $108.0M | $122.7M | $122.5M | $114.0M |
| Short-term investments | $248.5M | $60.0M | $98.4M | $67.9M | $59.7M | $209.4M |
| Total debt | $70.0M | $48.2M | $16.9M | $0.00 | $0.00 | $0.00 |
| Total assets | $763.6M | $580.6M | $526.3M | $459.7M | $232.8M | $349.5M |
| Total liabilities | $196.0M | $142.1M | $87.5M | $63.5M | $47.8M | $37.5M |
| Shareholders' equity | $567.6M | $438.4M | $438.8M | $396.1M | $185.0M | $311.9M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology